Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

被引：404

作者：

Jenkins, Russell W. ^{[1
,2
]}

Aref, Amir R. ^{[1
,3
]}

Lizotte, Patrick H. ^{[1
,3
]}

Ivanova, Elena ^{[1
,3
]}

Stinson, Susanna ^{[4
]}

Zhou, Chensheng W. ^{[1
,5
]}

Bowden, Michaela ^{[1
,5
]}

Deng, Jiehui ^{[1
]}

Liu, Hongye ^{[1
,3
,6
]}

Miao, Diana ^{[1
,7
,8
]}

He, Meng Xiao ^{[1
,7
,8
,9
]}

Walker, William ^{[1
,3
]}

Zhang, Gao ^{[10
,11
]}

Tian, Tian ^{[12
]}

Cheng, Chaoran ^{[12
]}

Wei, Zhi ^{[12
]}

Palakurthi, Sangeetha ^{[1
,3
]}

Bittinger, Mark ^{[1
,3
]}

Vitzthum, Hans ^{[2
]}

Kim, Jong Wook ^{[1
,7
,8
]}

Merlino, Ashley ^{[1
]}

Quinn, Max ^{[1
]}

Venkataramani, Chandrasekar ^{[4
]}

Kaplan, Joshua A. ^{[4
]}

Portell, Andrew ^{[1
,3
]}

Gokhale, Prafulla C. ^{[1
,3
]}

Phillips, Bart ^{[4
]}

Smart, Alicia ^{[1
,7
,8
]}

Rotem, Asaf ^{[1
]}

Jones, Robert E. ^{[1
,3
]}

Keogh, Lauren ^{[1
,3
]}

Anguiano, Maria ^{[13
]}

Stapleton, Lance ^{[4
]}

Jia, Zhiheng ^{[4
]}

Barzily-Rokni, Michal ^{[2
]}

Canadas, Israel ^{[1
]}

Thai, Tran C. ^{[1
]}

Hammond, Marc R. ^{[2
]}

Vlahos, Raven ^{[1
,5
]}

Wang, Eric S. ^{[14
]}

Zhang, Hua ^{[1
]}

Li, Shuai ^{[1
]}

Hanna, Glenn J. ^{[1
]}

Huang, Wei ^{[1
,3
]}

Hoang, Mai P. ^{[15
]}

Piris, Adriano ^{[16
,17
]}

Eliane, Jean-Pierre ^{[15
]}

Stemmer-Rachamimov, Anat O. ^{[15
]}

Cameron, Lisa ^{[18
]}

Su, Mei-Ju ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Div Med Oncol, Boston, MA USA

[3] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA 02115 USA

[4] Gilead Sci, Foster City, CA USA

[5] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA

[6] Harvard Med Sch, Lab Syst Pharmacol, Boston, MA USA

[7] Broad Inst Harvard, Cambridge, MA USA

[8] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA

[9] Harvard Grad Program Biophys, Boston, MA USA

[10] Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA

[11] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA

[12] New Jersey Inst Technol, Dept Comp Sci, Newark, NJ 07102 USA

[13] Univ Navarra, Ctr Appl Med Res, Pamplona, Spain

[14] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA

[15] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA

[16] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA

[17] Harvard Med Sch, Boston, MA USA

[18] Dana Farber Canc Inst, Confocal & Light Microscopy Core Facil, Boston, MA 02115 USA

[19] Harvard Med Sch, Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA

[20] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA

[21] Harvard Med Sch, Brigham & Womens Hosp, Dept Surg Oncol, Boston, MA USA

[22] MIT, Dept Mech Engn, Cambridge, MA 02139 USA

[23] Harvard Med Sch, Brigham & Womens Hosp, Div Thorac Surg, Boston, MA USA

[24] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA

来源：

CANCER DISCOVERY | 2018年 / 8卷 / 02期

关键词：

IMMUNE-CHECKPOINT BLOCKADE; REGULATORY T; KINASE TBK1; CANCER; RESISTANCE; CELLS; CTLA-4; MELANOMA; IMMUNOTHERAPY; PEMBROLIZUMAB;

D O I：

10.1158/2159-8290.CD-17-0833

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ex vivo systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination therapies. Here, we demonstrate the ability to interrogate ex vivo response to ICB using murine-and patient-derived organotypic tumor spheroids (MDOTS/PDOTS). MDOTS/PDOTS isolated from mouse and human tumors retain autologous lymphoid and myeloid cell populations and respond to ICB in short-term three-dimensional microfluidic culture. Response and resistance to ICB was recapitulated using MDOTS derived from established immunocompetent mouse tumor models. MDOTS profiling demonstrated that TBK1/IKKe inhibition enhanced response to PD-1 blockade, which effectively predicted tumor response in vivo. Systematic profiling of secreted cytokines in PDOTS captured key features associated with response and resistance to PD-1 blockade. Thus, MDOTS/PDOTS profiling represents a novel platform to evaluate ICB using established murine models as well as clinically relevant patient specimens. SIGNIFICANCE: Resistance to PD-1 blockade remains a challenge for many patients, and biomarkers to guide treatment are lacking. Here, we demonstrate feasibility of ex vivo profiling of PD-1 blockade to interrogate the tumor immune microenvironment, develop therapeutic combinations, and facilitate precision immuno-oncology efforts. (C) 2017 AACR.

引用

页码：196 / 215

页数：20

共 50 条

[21] PD-1 BLOCKADE ENHANCES THE EFFICACY OF ELOTUZUMAB IN MOUSE TUMOR MODELS
Bezman, N.
Jhatakia, A.
Kearney, A.
Brender, T.
Maurer, M.
Sum, C.
Lei, M.
Waggie, K.
Postelnek, J.
Henning, K.
Jenkins, M.
Rogers, A.
Neeson, P.
Korman, A.
Robbins, M.
Graziano, R.
HAEMATOLOGICA, 2016, 101 : 161 - 162
[22] Tumor specific γδ T cells expand and respond to PD-1 blockade
Lien, Scott C.
Ly, Dalam
Yang, S. Y. Cindy
Wang, Ben X.
St Paul, Michael
Gadalla, Ramy
Noamani, Babak
Boross-Harmer, Sarah
Pugh, Trevor J.
Spreafico, Anna
Hirano, Naoto
Razak, Albiruni R. A.
Ohashi, Pamela S.
CANCER IMMUNOLOGY RESEARCH, 2023, 11 (12)
[23] USE OF HDACI AND PD-1/PD-LI BLOCKADE TO ENHANCE CYTOLYTIC ACTIVITY OF EX VIVO EXPANDED NK CELLS AGAINST NEUROBLASTOMA
Shen, S.
Dolnikov, A.
O'Brien, T.
CYTOTHERAPY, 2016, 18 (06) : S64 - S64
[24] PD-1 blockade: promoting endogenous anti-tumor immunity
Peggs, Karl S.
Quezada, Sergio A.
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (10) : 1279 - 1282
[25] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
Lin, Heng
Wei, Shuang
Vatan, Linda
Kryczek, Ilona
Zou, Weiping
JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
[26] Nonuniform T-cell infiltration induced by PD-1 checkpoint blockade, ex vivo, predicts distinct clinical response
Smalley, Munisha
Shanthappa, Basavaraja
Gertje, Hans
Lawson, Mark
Ulaganathan, Baraneedharan
Thayakumar, Allen
Doval, D. C.
Mehta, Anurag
Somashekhar, S. P.
Radhakrishnan, Padhma
Majumder, Pradip
Goldman, Aaron J.
CANCER RESEARCH, 2018, 78 (13)
[27] Resistance to PD-1 blockade in melanoma
Burki, Talha Khan
LANCET ONCOLOGY, 2016, 17 (09): : E376 - E376
[28] PD-1 blockade therapy for cancer
Ribas, Antoni
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10)
[29] Biology of PD-1 Checkpoint Blockade
Sharpe, Arlene H.
BLOOD, 2017, 130
[30] Cancer immunotherapy by PD-1 blockade
Honjo, Tasuku
CANCER SCIENCE, 2018, 109 : 197 - 197

← 1 2 3 4 5 →